Table 2 Selected studies presentation for fluoxetine

Fabre et al. [15]

Age 21–70

HAM-D ≥ 20

5

Fluoxetine

Placebo

40–80

22

26

-0.8 (0.1)

0.50

0.44

Stark et al. [16]

DSM-III, Age 18–70

HAM-D₂₁ ≥ 20

40

0.32

6

Fluoxetine

Placebo

20–80

185

169

-0.3(0.01)

0.63

0.38

0.37

0.45

Cohn et al. [17]

DSM-III, Age 20–64

HAM-D ≥ 20

41

0.40

6

Fluoxetine

Placebo

20–80

54

57

-1.3(0.04)

0.72

0.30

0.30

0.72

Fieve et al. [18]

DSM-III, Age 18–65

HAM-D₂₁ ≥ 20

0.57

6

Fluoxetine

Fluoxetine

Fluoxetine

Placebo

5

20

40

14

13

13

9

-0.5 (0.1)

Rickels et al. [19]

DSM-III, Age 21–70

HAM-D ≥ 20

47.2

0.21

5

Fluoxetine

Placebo

20–80

18

24

-0.7 (0.2)

0.90

0.39

Goodnick et al. [20]

DSM-III, Age 18–65

HAM-D ≥ 116

0.54

7

Fluoxetine

Placebo

20–60

30

5

-1.1(0.3)

0.1(0.2)

Wernicke et al. [21]

DSM-III, Age 18–65

HAM-D ≥ 20

39.8

0.43

6

Fluoxetine

Fluoxetine

Fluoxetine

Placebo

20

40

60

97

97

103

48

-0.5(0.03)

-0.5(0.03)

-0.2(0.03)

0.53

0.61

0.48

0.27

0.38

0.40

0.55

0.44

Fabre et al. [22]

DSM-III, Age 18–65

HAM-D ≥ 14

6

Fluoxetine

Fluoxetine

Fluoxetine

Placebo

20

40

60

22

25

25

12

-2.1 (0.4)

-1.5 (0.3)

-2.3 (0.5)

0.67

0.31

1

0

Wernicke et al. [23]

DSM-III, Age 18–65

HAM-D ≥ 14

39

0.37

6

Fluoxetine

Fluoxetine

Fluoxetine

Placebo

5

20

40

94

91

92

77

-0.5(0.02)

-0.4(0.02)

-0.5(0.02)

0.54

0.64

0.65

0.33

Harto et al. [24]

DSM-III, Age 18–65

HAM-D ≥ 20

38.4

43.8

36.4

0.37

0.37

0.37

6

Fluoxetine

Fluoxetine

Fluoxetine

Placebo

5

20

40

8

10

9

8

1 (0.3)

1.1 (0.3)

0.9 (0.3)

Byerley et al. [25]

DSM-III

HAM-D₂₁ ≥ 20

38.9

0.31

6

Fluoxetine

Placebo

40–80

32

29

-1.1 (0.1)

0.38

0.45

Muijen et al. [26]

Research Diagnostic Criteria, Age 18–65

HAMD-D17 ≥ 17

35.8

0.37

6

Mianserin

Fluoxetine

Placebo

20

20

27

26

28

-1.2 (0.2)

0.55

0.23

0.46

0.43

Feighner et al. [27]

DSM-III, Age 18–70

HAMD-D21 ≥ 20, RSDM ≥ 8 and RSDM ≥ Covi

45

0.26

6

Imipramine

Fluoxetine

Placebo

150

80 (median)

46

51

48

-0.3(0.04)

0.51

0.68

Dunlop et al. [28]

DSM-III, Age 18–65

HAMD-D ≥ 14 and RSDM >Covi

39.3

39.3

39.3

6

Fluoxetine

Fluoxetine

Fluoxetine

Placebo

20

40

60

103

99

97

56

-0.1(0.03)

-0.03 (0.03)

0.1(0.03)

0.53

0.51

0.59

0.36

0.35

0.41

0.39

0.34

Valducci et al. [29]

DSM-III-R, Age 19–67

HAMD-D >18

0.43

8

Fluoxetine

Placebo

20

20

20

-0.9 (0.1)

0.70

0.25

Heiligenstein et al. [31]

DSM-III-R, Age 18–65

HAMD-D17 ≥ 15

44.4

8

Fluoxetine

Placebo

20

46

43

0.1 (0.1)

-0.9 (0.1)

0.61

0.41

Sramek et al. [32]

DSM-III-R, Age 18–65

HAMD-D24 ≥ 21 with item 1 ≥ 2, HAM-A ≤ 18, HAMD-D24 <HAM-A, RSDM ≥ 8 and RSDM >Covi

33.9

0.40

9

ABT-200

Fluoxetine

Placebo

160–320

20

72

72

72

-0.3(0.03)

0.17

0.13

Fava et al. [33]

DSM-III-R, Age (mean 41,3) HAMD-D17 ≥ 18, Raskin depression score ≥ 8 and superior to Raskin anxiety score

41.3

0.49

12

Paroxetine

Fluoxetine

Placebo

20–50

20–80

55

54

19

0.1 (0.1)

0.57

0.53

Rudolph et al. [34]

DSM-IV, Age > 18

HAMD-D21 ≥ 20

40

0.33

8

Venlafaxine

XR

Fluoxetine

Placebo

75–225

20–60

100

103

98

-0.2(0.02)

0.50

0.42

0.27

0.21

Coleman et al. [35]

DSM-IV, Age 18–76

HAMD-D21 ≥ 20

37.1

8

Bupropion SR

Fluoxetine

Placebo

150–400

20–60

150

154

152

-0.2(0.01)

0.57

0.50

0.37

0.33

Goldstein et al. [9]

DSM-IV, Age 18–65

HAMD-D17 ≥ 15 and CGI-S ≥ 4

39.7

0.35

8

Duloxetine

Fluoxetine

Placebo

40–120

20

70

33

70

-0.2(0.04)

0.45

0.39

0.36

0.34

Silverstone et al. [42]

DSM-IV, Age ≥ 18

HAMD-D21 ≥ 20 (on the first 17 items), Covi ≥ 8

43.2

0.4

12

Fluoxetine

Venlafaxine

XR

Placebo

20–60

75–225

121

128

119

-0.6(0.02)

0.62

0.43

0.26

0.40

Globally

40 ± 3

0.39

7 ± 2

Fluoxetine

Placebo

20–80

2078

1093

-0.46(0.11)

0.37(0.09) **

-0.02(0.09) **